Futurism11h
Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal
As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.
A woman who lost 130 pounds shares 7 changes she wasn't expecting — from people being nicer to her to food tasting different
Emma Roma Jayne lost 130 pounds in two years, and says people treat her very differently.
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the ...
Senate Republican questions FDA chief on counterfeit weight loss drugs
Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...
Where Will Hims & Hers Stock Be in Five Years? Here’s What This Top Investor Expects
Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...
The Average Weight for American Women
The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are mathematical calculations, so they don’t necessarily represent what’s typical or ...
ConsumerAffairs3d
Tirzepatide vs. semaglutide for weight loss
Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.